Why we invested in Generation Lab, turning biological age into actionable insight
Most people, along with their clinicians, lack reliable tools to understand how fast their bodies are aging. By the time standard tests detect an issue, damage is often already done.
Generation Lab is changing this. The company’s flagship diagnostic, SystemAge™, is the world’s fastest-growing longevity platform. It measures biological aging across 19 organ systems from intact primary blood data, without relying on arbitrary transformations or approximations. Instead of producing a single, inconsistent “biological age” number, SystemAge™ provides a detailed organ-level report and personalized insights that help clinicians and consumers track the effects of therapies, lifestyle changes, or preventative interventions in a measurable way.
By detecting biological changes at the molecular level, SystemAge™ also enables true preventive medicine—spotting early signs of dysfunction long before symptoms appear. It empowers people to not only slow or reverse aging but also prevent disease progression before it takes hold.
In under a year since launch, Generation Lab has achieved extraordinary commercial traction, signing more than 275 clinics worldwide, including leading longevity physicians and wellness centers. The company has already generated over 300 million human-aging data points, supporting 99.9% diagnostic accuracy and establishing SystemAge™ as the most rapidly adopted longevity diagnostic platform in the market.
The company’s technology is validated by extensive in-clinic results showing measurable biological age reversals, including 13.6 years in brain function and 4.9 years in reproductive system health after targeted interventions.
Co-founder Professor Irina Conboy of UC Berkeley is a world leader in aging and regenerative biology, cited more than 12,000 times in academic literature. Her discovery of the non-linear physiologic curve of DNA methylation aging underpins the SystemAge™ model. CEO and co-founder Alina Su, a Harvard Medical School PhD candidate in Biological and Biomedical Science, serial Biotech entrepreneur. COO Michael Suswal co-founded Standard AI, which raised over $250 million and reached a valuation exceeding $1 billion.
Consumer longevity is entering its next phase. Public figures and investors alike are propelling the field forward, with global funding surpassing $8.4 billion in 2024. Yet, until now, measurement tools have lagged behind the hype. SystemAge™ closes that gap by providing the precision and scalability needed to make longevity diagnostics part of mainstream preventive healthcare.
At Samsung Next, we look for founders building the infrastructure of the future. Generation Lab stands out for its:
Scientific rigor: technology built on decades of validated academic research and hundreds of millions of real-world data points
Market readiness: rapid adoption across both clinical and consumer longevity markets
Strategic potential: opportunities to integrate epigenetic diagnostics with Samsung’s consumer health ecosystem, combining wearable and biomarker data for continuous, personalized health tracking
Generation Lab’s long-term vision is to build an AI-powered, closed-loop longevity platform that enables people to not only measure but meaningfully reverse biological aging. As longevity transitions from niche interest to clinical standard, we believe Generation Lab is poised to become the trusted authority for aging measurement and optimization.
That’s why we’re proud to back Generation Lab as part of its $11 million seed funding round led by Accel, alongside Steve Aoki, Giannis Antetokounmpo, and Simu Liu.
Diane Choi is an investor at Samsung Next. Samsung Next’s investment strategy is limited to its own views and does not reflect the vision or strategy of any other Samsung business unit, including, but not limited to, Samsung Electronics.